Article
NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: a randomized controlled trial for pharmacogenetics-based therapy.
European journal of clinical pharmacology - 1 May 2013
Azuma Junichi, Ohno Masako, Kubota Ryuji, Yokota Soichiro, Nagai Takayuki, Tsuyuguchi Kazunari, Okuda Yasuhisa, Takashima Tetsuya, Kamimura Sayaka, Fujio Yasushi, Kawase Ichiro
Abstract excerpt
OBJECTIVE: This study is a pharmacogenetic clinical trial designed to clarify whether the N-acetyltransferase 2 gene (NAT2) genotype-guided dosing of isoniazid improves the tolerability and efficacy of the 6-month four-drug standard regimen for newly diagnosed pulmonary tuberculosis. METHODS: In a multicenter, parallel, randomized, and controlled trial with a PROBE design, patients were assigned to either...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.